1.
Ann Rheum Dis
; 81(12): e239, 2022 Dec.
Article
in English
| MEDLINE | ID: covidwho-2117976
Subject(s)
COVID-19 , Kava , Mucocutaneous Lymph Node Syndrome , Child , Humans , SARS-CoV-2 , Mucocutaneous Lymph Node Syndrome/diagnosis
2.
Am J Public Health
; 111(4): 577-581, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-1390500
Subject(s)
COVID-19 Vaccines , COVID-19 , Emigrants and Immigrants/statistics & numerical data , Health Communication , Health Services Accessibility , Vaccination/trends , COVID-19 Vaccines/administration & dosage , COVID-19 Vaccines/supply & distribution , Humans , Medically Underserved Area , United States
3.
Open Forum Infect Dis
; 8(5): ofab180, 2021 May.
Article
in English
| MEDLINE | ID: covidwho-1246746
ABSTRACT
As the first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines passed UK and US regulatory milestones in late 2020 and early 2021, multiple professional societies offered recommendations to assist pregnant and breastfeeding people as they choose whether to undergo vaccination. Despite such guidance, the lack of data describing vaccine safety, immunogenicity, and efficacy in pregnant and breastfeeding people has made this decision challenging for many. However, even considering the paucity of data, the known risks of coronavirus disease 2019 during pregnancy likely outweigh the not yet fully elucidated risks of SARS-CoV-2 vaccines, which have reassuring safety and efficacy profiles among nonpregnant people.